Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Chula Vista, California


Purpose:

The purpose of this study is to investigate the safety and tolerability of AZD5658 following ascending single oral doses in Type 2 Diabetics. It will also estimate the maximum tolerated dose.


Study summary:

This is a randomized, single-blind, placebo-controlled, single-center, phase 1 study to assess the safety, tolerability, pharmacokinetics, pharmacodynamics and the effect of fasting after single ascending oral doses of AZD5658 in type 2 diabetes mellitus patients.


Criteria:

Inclusion Criteria: - Patients must be of non-childbearing potential. - Body mass index between greater than or equal to 19 and less than or equal to 40 kg/m2 - Patients with confirmed Type 2 Diabetes diagnosis for at least 1 year and treated with Metformin Exclusion Criteria: - Clinically significant illness or clinically relevant trauma within 2 weeks before the first administration of the IP - Participation in another clinical study during the last 30 days prior to enrollment - Significant cardiovascular event within the last 6 months prior to enrollment


NCT ID:

NCT01176097


Primary Contact:

Study Director
Karin Wahlander
AstraZeneca R&DPepparedsleden 1431 83 M�lnda


Backup Contact:

N/A


Location Contact:

Chula Vista, California
United States



There is no listed contact information for this specific location.

Site Status: N/A


Data Source: ClinicalTrials.gov

Date Processed: August 31, 2019

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.